In the prevention of dementia, the focus should be on early and consistent treatment of hypertension

Česká verzia

Authors: Miroslav Souček
Authors place of work: II. interní klinika FN u sv. Anny v Brně
Published in the journal: Vnitř Lék 2023; 69(4): 249-253
Category: Review Articles
doi: https://doi.org/10.36290/vnl.2023.047

Summary

The brain is among the target organs of hypertension. Patients with hypertension have a higher risk of developing stroke as well as experiencing a decline in cognitive functions and dementia. Changes in the white matter and atrophy of the grey matter of the brain induced by high blood pressure develop insidiously since the onset of hypertension, even in young individuals. The effect of high blood pressure on the vessel wall cumulates in time; therefore, hypertension in younger people implies an increased risk of dementia in older age. Hypertension in young age cannot be considered a benign condition. Hypertension in middle age increases the risk of dementia by 61 %. Consistent and early hypertension control can reverse the adverse development towards dementia and lack of self-sufficiency in the patient. Data comparing individual antihypertensive drugs in terms of preventing dementia are scarce. However, renin angiotensin system blockers have been found to protect against Alzheimer’s disease more than other classes of antihypertensive drugs. To achieve rapid and effective hypertension control, a combination of antihypertensive drugs is usually required. Using a fixed-dose triple combination of perindopril, indapamide, and amlodipine, blood pressure targets of < 130/80 mm Hg can be achieved within three months in 93 % of patients.

Keywords:

dementia – hypertension – cognitive function – hypertension-induced end-organ damage – RAS inhibitors – ACEI – sartans – fixed-dose triple combination of antihypertensive drugs – Triplixam

Zdroje

1. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-1222. Dostupné na: http://www.healthdata. org/czech‑republic.

2. Henskens LH, van Oostenbrugge RJ, Kroon AA, et al. Detection of silent cerebrovascular disease refines risk stratification of hypertensive patients. J Hypertens. 2009 Apr;27(4):846-853.

3. Madsen TE, Howard G, Kleindorfer DO, et al. Sex Differences in Hypertension and Stroke Risk in the REGARDS Study: A Longitudinal Cohort Study. Hypertension. 2019 Oct;74(4):749-755.

4. Elyas S, Adingupu D, Aizawa K, et al. Cerebral small vessel disease, systemic vascular characteristics and potential therapeutic targets. Aging (Albany NY). 2021 Sep 22;13(18):22030–22039.

5. Melgarejo J, Vernooij MW, Ikram MA, et al. Intracranial carotid arteriosclerosis mediates the association between blood pressure and cerebral small vessel disease: the Rotterdam Study. Prezentováno na kongresu ESC 2022 v Barceloně.

6. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 2011 Sep;10(9):819-828.

7. Sierra C, de La Sierra A, Mercader J, et al. Silent cerebral white matter lesions in middle‑aged essential hypertensive patients. J Hypertens. 2002 Mar;20(3):519-524.

8. Schaare HL, Kharabian Masouleh S, et al. Association of peripheral blood pressure with gray matter volume in 19- to 40-year‑old adults. Neurology. 2019 Feb 19;92(8):e758-e773.

9. Wohlfahrt P. Cognitive impairment and the threat of dementia pandemic or the journey of hypertensive patients to self‑care deficit. Vnitr Lek. 2022 Winter;68(8):532-536.

10. Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997 Mar 12;277(10):813-817.

11. Wang N, Harris K, Hamet P, et al. Cumulative Systolic Blood Pressure Load and Cardiovascular Risk in Patients With Diabetes. J Am Coll Cardiol. 2022 Sep 20;80(12):1147-1155.

12. Suvila K, McCabe EL, Lehtonen A, et al. Early Onset Hypertension Is Associated With Hypertensive End‑Organ Damage Already by MidLife. Hypertension. 2019 Aug;74(2):305-312.

13. Maillard P, Mitchell GF, Himali JJ, et al. Effects of Arterial Stiffness on Brain Integrity in Young Adults From the Framingham Heart Study. Stroke. 2016 Apr;47(4):1030-1036.

14. Shang X, Hill E, Zhu Z, et al. The Association of Age at Diagnosis of Hypertension With Brain Structure and Incident Dementia in the UK Biobank. Hypertension. 2021 Nov;78(5):1463-1474.

15. Lee CJ, Hwang J, Kang CY, et al. Protective effect of controlled blood pressure on risk of dementia in low‑risk, grade 1 hypertension. J Hypertens. 2021 Aug 1;39(8):1662-1669.

16. SPRINT MIND Investigators for the SPRINT Research Group. Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions. JAMA. 2019 Aug 13;322(6): 524-534.

17. Ungvari Z, Toth P, Tarantini S, et al. Hypertension‑induced cognitive impairment: from pathophysiology to public health. Nat Rev Nephrol. 2021 Oct;17(10):639-654.

18. Barthold D, Joyce G, Wharton W, et al. The association of multiple anti‑hypertensive medication classes with Alzheimer’s disease incidence across sex, race, and ethnicity. PLoS One. 2018 Nov 1; 13(11):e0206705.

19. Nedogoda SV, Ledyaeva AA, Chumachok EV, et al. Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. Clin Drug Investig. 2013 Aug;33(8):553-561.

20. Nedogoda SV, Ledyaeva AA, Chumachok EV, et al. Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. Clin Drug Investig. 2013 Aug;33(8):553-561.

21. van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin‑converting enzyme inhibitors reduce mortality in hypertension: a meta‑analysis of randomized clinical trials of renin‑angiotensin‑aldosterone system inhibitors involving 158,998 patients. Eur Heart J. 2012 Aug;33(16):2088-2097.

22. Lv J, Perkovic V, Foote CV, et al. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev. 2012 Dec 12;12:CD004136.

23. Baker WL, Coleman CI, Kluger J, et al. Systematic review: comparative effectiveness of angiotensin‑converting enzyme inhibitors or angiotensin II‑receptor blockers for ischemic heart disease. Ann Intern Med. 2009 Dec 15;151(12):861-871.

24. Lévy BI, Mourad JJ. Renin Angiotensin Blockers and Cardiac Protection: From Basis to Clinical Trials. Am J Hypertens. 2022 Apr 2;35(4):293-302.

25. Logunova N, Khomitskaya Y, Karpov Y, et al. Antihypertensive effectiveness and tolerability of perindopril/indapamide/amlodipine triple single-pill combination in the treatment of patients with arterial hypertension (TRICOLOR), J Hypertens. 2021;39:e373.

26. Cicero AFG, Fogacci F, Rizzoli E, et al. Long‑Term Impact of Different Triple Combination Antihypertensive Medications on Blood Pressure Control, Metabolic Pattern and Incident Events: Data from the Brisighella Heart Study. J Clin Med. 2021 Dec 17;10(24):5921.